98%
921
2 minutes
20
Objectives: Neurostimulation interventions often face heightened barriers limiting patient access. The objective of this study is to examine different stakeholders' perceived barriers to using different neurostimulation interventions for depression.
Methods: We administered national surveys with an embedded experiment to 4 nationwide samples of psychiatrists (n = 505), people diagnosed with depression (n = 1050), caregivers of people with depression (n = 1026), and members of the general public (n = 1022). We randomly assigned respondents to 1 of 8 conditions using a full factorial experimental design: 4 neurostimulation modalities (electroconvulsive therapy [ECT], repetitive transcranial magnetic stimulation [rTMS], deep brain stimulation [DBS], or adaptive brain implants [ABIs]) by 2 depression severity levels (moderate or severe). We asked participants to rank from a list what they perceived as the top 3 barriers to using their assigned intervention. We analyzed the data with analysis of variance and logistic regression.
Results: Nonclinicians most frequently reported "limited evidence of the treatment's effectiveness" and "lack of understanding of intervention" as their top 2 most important practical barriers to using ECT and TMS, respectively. Compared with nonclinicians, psychiatrists were more likely to identify "stigma about treatment" for ECT and "lack of insurance coverage" for TMS as the most important barriers.
Conclusions: Overall, psychiatrists' perceptions of the most important barriers to using neurostimulation interventions were significantly different than those of nonclinicians. Perceived barriers were significantly different for implantable DBS and ABI) versus nonimplantable (rTMS and ECT) neurostimulation interventions. Better understanding of how these barriers vary by neurostimulation and stakeholder group could help us address structural and attitudinal barriers to effective use of these interventions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136602 | PMC |
http://dx.doi.org/10.1097/YCT.0000000000000990 | DOI Listing |
Chest
September 2025
Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Bedford Park, South Australia, Australia.
Background: Hypoglossal nerve stimulation (HNS) to treat obstructive sleep apnea (OSA) currently requires placement of a cuff or 'saddle' electrode around or adjacent to the hypoglossal nerve(s). Limitations for this therapy include cost, invasiveness, and variable efficacy.
Research Question: Can HNS applied via percutaneous implantation of a linear, multi-pair electrode array restore airflow to airway narrowing and/or obstruction, and improve airway collapsibility in people with OSA?
Study Design And Methods: Participants with OSA undergoing drug induced sleep endoscopy with propofol were instrumented with an epiglottic pressure catheter, nasal mask and pneumotachograph.
Eur J Neurol
September 2025
Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Torino, Italy.
Background: The factors contributing to a poor response to subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) are not yet fully understood. Accordingly, predicting the outcome might be challenging particularly in those who display an optimal response to the Levodopa challenge test.
Objective: To determine which factors may contribute to poor outcome of STN-DBS in PD.
Front Neurol
August 2025
Department of Rehabilitation Therapy Teaching and Research, Gannan Healthcare Vocational College, Ganzhou, Jiangxi, China.
Background: Magnetic seizure therapy (MST) is an innovative neurostimulation technique. While MST shares similarities with other neuromodulation techniques, such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS), most research has predominantly focused on its efficacy. However, there is a notable scarcity of studies addressing MST's safety.
View Article and Find Full Text PDFEpilepsy Res
August 2025
University of Colorado School of Medicine, Aurora, CO, USA.
Objectives: Responsive neurostimulation (RNS) electrocorticographic (ECoG) data may have a role in objectively assessing the efficacy of add-on antiseizure medications (ASMs). This retrospective, multicenter, observational, 24-week study is the first to report the effects of cenobamate on RNS-detected events (RDE).
Methods: Patients included adults (≥18 years) with a history of recurrent focal seizures and implanted RNS who initiated adjunctive cenobamate ≥ 3 months after RNS implant between 4/1/20-12/15/23 and who received ≥ 2 weeks of cenobamate (≥50 mg/day).
J Neurosurg
September 2025
4Carle Illinois College of Medicine, University of Illinois Urbana-Champaign, Champaign, Illinois.
Objective: Major depressive disorder is a significant cause of disability, impacting an estimated 193 million individuals worldwide. Forty percent are estimated to have little to no response to standard pharmacological therapies. Deep brain stimulation (DBS) has emerged as a favorable neuromodulation therapy for treatment-resistant depression, but it remains unclear which brain targets are optimal.
View Article and Find Full Text PDF